ImmunityBio, Inc. (IBRX): Results of Operations and Financial Condition
ImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ibrx-202684x8kexhibit991.htm EX-99.1 Document EXHIBIT 99.1 ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million • Q2 2026 net product revenue of $50.7 million, up 92% year-over-year a
How this was made
The 30-second read
Why it matters
Traders can update risk pricing for ANKTIVA based on the newly disclosed FDA sBLA acceptance and the assigned PDUFA target date, while also tracking whether commercial adoption sustains the reported sequential revenue growth.
Market read
Strong reported revenue growth plus a specific FDA review timeline are the two actionable catalysts for IBRX risk and positioning.
What to watch
The 8-K emphasizes regulatory and pipeline milestones but does not quantify expected impact from upcoming sBLA submissions (e.g., QUILT-2.005) or provide new efficacy data that would materially shift approval probability today.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial and operational results plus regulatory updates for ANKTIVA.
Ticker impact
ImmunityBio reports Q2 2026 net product revenue of $50.7M (+92% YoY) and an FDA sBLA acceptance for ANKTIVA plus BCG with a Jan 6, 2027 PDUFA date.
Moderately positive bias into the FDA PDUFA window, with volatility around any interim regulatory/clinical updates.
This 8-K discloses both financial performance and a specific FDA action date (Jan 6, 2027), typically a catalyst for biotech risk pricing. The magnitude of revenue growth supports the commercial adoption narrative, but the text does not provide trial efficacy results that would directly change the approval odds today.
Market effects
Reinforces investor focus on IL-15 receptor agonist platform commercialization plus regulatory progress in NMIBC and NSCLC.
No direct regional market impact beyond expanding ANKTIVA authorization footprint to 34 countries.
Highlights additional international marketing authorization progress (UAE) alongside FDA review, supporting global adoption expectations.
Counterpoint
Revenue growth may be partially offset by rising non-cash fair value and derivative-driven losses, so equity risk can remain high despite operational progress.
Key entities
- issuerImmunityBio, Inc.
Commercial-stage biotech reporting Q2 2026 results and FDA review progress for ANKTIVA.
- productANKTIVA
IL-15 receptor agonist referenced as the driver of net product revenue and the subject of the FDA sBLA acceptance.
- regulatorFDA
Accepted the company’s supplemental BLA and assigned a Jan 6, 2027 PDUFA target date.
- partnerJapan BCG Laboratory
Entered into an exclusive development and supply agreement for intravesical Tokyo-172 BCG with exclusive U.S. rights.
